739 related articles for article (PubMed ID: 11557981)
1. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
2. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
3. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
4. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
[TBL] [Abstract][Full Text] [Related]
5. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
[TBL] [Abstract][Full Text] [Related]
6. Strategies for target cell recognition by natural killer cells.
Diefenbach A; Raulet DH
Immunol Rev; 2001 Jun; 181():170-84. PubMed ID: 11513138
[TBL] [Abstract][Full Text] [Related]
7. NKG2D-independent suppression of T cell proliferation by H60 and MICA.
Kriegeskorte AK; Gebhardt FE; Porcellini S; Schiemann M; Stemberger C; Franz TJ; Huster KM; Carayannopoulos LN; Yokoyama WM; Colonna M; Siccardi AG; Bauer S; Busch DH
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11805-10. PubMed ID: 16091471
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
9. Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D.
Cerwenka A; O'Callaghan CA; Hamerman JA; Yadav R; Ajayi W; Roopenian DC; Joyce S; Lanier LL
J Immunol; 2002 Apr; 168(7):3131-4. PubMed ID: 11907062
[TBL] [Abstract][Full Text] [Related]
10. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
[TBL] [Abstract][Full Text] [Related]
12. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
Regunathan J; Chen Y; Wang D; Malarkannan S
Blood; 2005 Jan; 105(1):233-40. PubMed ID: 15328154
[TBL] [Abstract][Full Text] [Related]
13. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions.
Lodoen MB; Abenes G; Umamoto S; Houchins JP; Liu F; Lanier LL
J Exp Med; 2004 Oct; 200(8):1075-81. PubMed ID: 15477345
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin.
Hayakawa Y; Kelly JM; Westwood JA; Darcy PK; Diefenbach A; Raulet D; Smyth MJ
J Immunol; 2002 Nov; 169(10):5377-81. PubMed ID: 12421908
[TBL] [Abstract][Full Text] [Related]
15. EAE tolerance induction with Hsp70-peptide complexes depends on H60 and NKG2D activity.
Galazka G; Jurewicz A; Orlowski W; Stasiolek M; Brosnan CF; Raine CS; Selmaj K
J Immunol; 2007 Oct; 179(7):4503-12. PubMed ID: 17878346
[TBL] [Abstract][Full Text] [Related]
16. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.
Ogasawara K; Benjamin J; Takaki R; Phillips JH; Lanier LL
Nat Immunol; 2005 Sep; 6(9):938-45. PubMed ID: 16086018
[TBL] [Abstract][Full Text] [Related]
17. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection.
Feng L; Ke N; Ye Z; Guo Y; Li S; Li Q; Li Y
Transplant Proc; 2009 Dec; 41(10):4332-9. PubMed ID: 20005394
[TBL] [Abstract][Full Text] [Related]
18. Ligands for murine NKG2D display heterogeneous binding behavior.
Carayannopoulos LN; Naidenko OV; Kinder J; Ho EL; Fremont DH; Yokoyama W
Eur J Immunol; 2002 Mar; 32(3):597-605. PubMed ID: 11857333
[TBL] [Abstract][Full Text] [Related]
19. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
20. UL16 binding proteins.
Cao W; He W
Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
